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2010;105:1–5.3-Year Outcomes of the
OLIVE Registry, a
Prospective Multicenter
Study of Patients With
Critical Limb IschemiaWe read with much interest the recent paper and
editorial by Iida et al. (1) and Menard (2), respectively,
in JACC: Cardiovascular Interventions assessing the
mid-term outcomes after endovascular therapy in a
prospective multicenter (A Prospective, Multi-Center,
Three Year Follow-Up Study on Endovascular Treat-
ment for Infra-Inguinal Vessel in Patients With Critical
Limb Ischemia [OLIVE]) registry in 314 patients with
chronic limb ischemia (CLI). At 3 years, amputation-
free survival, freedom from major adverse limb
events, and wound-free survival rates were 55.2%,
84.0%, and 49.6%, respectively. Wound recurrence
rate was at 3 years was 43.9%. After multivariable
analysis, age (hazard ratio [HR]: 1.43, p ¼ 0.001), body
mass index 18.5 (HR: 2.17, p ¼ 0.001), dialysis (HR:
2.91, p < 0.001), and Rutherford 6 (HR: 1.64, p ¼ 0.047)
were identiﬁed as predictors of 3-year major ampu-
tation or death. Statin use (HR: 0.28, p ¼ 0.02),
Rutherford 6 (HR: 2.40, p ¼ 0.02), straight-line ﬂow to
the foot (HR: 0.27, p ¼ 0.001), and heart failure
(HR: 1.96, p ¼ 0.04) were identiﬁed as 3-year major
adverse limb event predictors. Finally, CLI due
to isolated, below-the-knee lesion was a wound
recurrence predictor (HR: 4.28, p ¼ 0.001). Three-yearsurvival, freedom from major amputation, and
reintervention rates were 63.0%, 87.9%, and 43.2%,
respectively.
The authors should be commended for writing
this important and timely paper, especially as the
research in CLI has reoriented towards optimizing
long-term patient outcomes. Long-term patient out-
comes beyond limb salvage are critical because large
registry studies in peripheral artery disease have
shown that suboptimal medical management in-
creases the risk of cardiovascular death, stroke, and
myocardial infarction by up to 7-fold at 3 years (3). In
this regard, it is striking that in the OLIVE registry,
despite a very high incidence of established vascular
disease (100%) and cardiovascular disease (21% to
46%), only 26% are on statin therapy, 40% on clopi-
dogrel, and/or 50% on cliostazol. Additionally, there
are no data presented on whether the statin use or
blood pressure control had been optimized and
reached the targets set by the TransAtlantic Inter-
Society Consensus (TASC) II guidelines (4). However,
the authors should be congratulated for reporting
on the degree of optimal medical therapy in their
patient subset. In fact, most of the recent prospective
studies have focused primarily on endovascular de-
vice use/techniques to optimize limb outcomes
and have not quantiﬁed whether patients received
guideline-based optimal medical therapy before or
after endovascular intervention (1).
These observations suggest a persistent deﬁcit in
the quality of medical care in CLI and have profound
implications. First, population-based interventions
that improve medical therapy for CLI may have a
large impact both on amputation-free survival and
reducing the risk of cardiovascular mortality and
myocardial infarction. Second, the addition of an
optimal medical treatment metric in the assessment
of endovascular and/or surgical interventions on CLI
will allow for uniform comparisons between different
treatment strategies. Furthermore, it is known that
the costs of inpatient care in the year before amputa-
tion in patients with CLI is more than $20,000 per
patient. This cost varies by 2-fold across hospital
referral regions in the United States; much of this
difference in cost is driven by the use of revasculari-
zation treatments and not related to patient or
amputation care. Additionally, there is little evidence
that higher spending on vascular care (primarily
endovascular care) in the year prior lowers amputa-
tion rates. The quality of baseline medical therapy
will be important in assessing and comparing the
overall quality and cost of vascular care pro-
vided by institutions and individual providers (5).
This is axiomatic in light of the environment in
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202which medicine is practiced today with the creation
of accountable care organizations and increasing
patient/payer scrutiny.*Femi Philip, MD
*Cardiovascular Medicine
University of California, Davis
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34–42.REPLY: 3-Year Outcomes of the
OLIVE Registry, a Prospective Multicenter
Study of Patients with Critical Limb IschemiaWe would like to thank Dr. Philip for his interest in
the OLIVE (A Prospective, Multi-Center, Three-Year
Follow-Up Study on Endovascular Treatment for
Infra-Inguinal Vessel in Patients With Critical Limb
Ischemia) registry (1) evaluating outcomes of endo-
vascular treatment for infrainguinal vessels in pa-
tients with critical limb ischemia (CLI). One issue that
was pointed out this time described problems in
the current treatments for patients with CLI. We
completely agree with Dr. Philip that the quality of
baseline medical therapy is extremely important
when assessing and comparing the overall quality
and cost of vascular care. As noted, we have
no evidence that the medical costs associated
with revascularization with endovascular therapy
actually prevent amputation, whereas the efﬁcacy of
optimal medical therapy (OMT) for amputation
prevention and prognosis improvement has not
been established, either (2). The current guidelinesrecommend OMT for peripheral arterial disease
(PAD) as follows: 1) antiplatelet therapy; 2) statins;
and 3) angiotensin-converting enzyme inhibitors/
angiotensin receptor blockers. There is a report that
the administration of 2 or more of these agents re-
duces mortality. However, we should also note the
lack of consistency in the provision and adherence
of these recommended therapies in PAD patients (3).
Some antiplatelet drugs and statins have been
reported to improve limb prognosis (2). The OLIVE
study demonstrated a low administration rate of sta-
tins in the real world. In this study, 52% of subjects
were on dialysis, 41% had hyperlipidemia, and the
mean body mass index was 22, but the administration
rate of statins was as low as 26%. Inadequate drug
treatment for PAD and poor adherence of patients
have recently been reported (4,5), and it is meaning-
ful that the OLIVE study also revealed that OMT is
rarely provided for CLI in actual clinical practice.
Among CLI patients in the clinical setting, some pre-
sented with hypotension or terminal status of arte-
riosclerosis with sarcopenia. For these patients facing
such a prognosis, both OMT administration and
revascularization are controversial. Either way, the
evidence level for the role of OMT for CLI is insufﬁ-
cient, and such veriﬁcation is urgently necessary.
The onset and progression of CLI are strongly
correlated with diabetes mellitus and renal failure.
Patients with these complications present with a
higher prevalence of infrainguinal arterial lesions,
which have a high rate of restenosis and reinterven-
tion after endovascular therapy. In the OLIVE study,
the percentage of subjects with diabetes mellitus and
those on dialysis was as high as 71% and 52%,
respectively, and approximately 75% had the infra-
popliteal arterial lesions, resulting in high rates of
restenosis and reintervention (1). In patients with rest
pain or ulcers/gangrene who developed a ﬁrst episode
or recurrence, reintervention seemed to be both
inevitable and the only option: the medical inter-
vention to prevent major amputations provides only
class III guidance in the current guideline. On the
other hand, repeated revascularization is an addi-
tional ﬁnancial burden, despite providing only local
treatment. A general treatment model, including
systemic treatment and social aspects, should be
considered in order to improve CLI prognosis as
well as medical cost burdens. Even if revasculariza-
tion is the ﬁrst-line treatment for CLI, this does not
necessarily justify repeated interventions performed
within a short period of time.Osamu Iida, MD
*Masato Nakamura, MD, PhD
